Does the media favor EXEL or IOVA?

In the previous week, Exelixis had 15 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 21 mentions for Exelixis and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Exelixis' score of 1.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IOVA or BMRN?

In the previous week, BioMarin Pharmaceutical had 6 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat BioMarin Pharmaceutical's score of 0.65 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or MDGL?

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 6 mentions for Iovance Biotherapeutics and 3 mentions for Madrigal Pharmaceuticals. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Madrigal Pharmaceuticals' score of 1.01 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or IOVA?

In the previous week, Halozyme Therapeutics had 14 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 20 mentions for Halozyme Therapeutics and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Halozyme Therapeutics' score of 0.74 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$8.43 -0.27 (-3.10%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$8.51 +0.08 (+0.89%)

As of 09/9/2026 07:59 PM Eastern

Compare

IOVA vs. EXEL, BMRN, MDGL, HALO, and ARWR

Should you buy Iovance Biotherapeutics stock or one of its competitors? Iovance Biotherapeutics's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Iovance Biotherapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Exelixis presently has a consensus price target of $50.07, indicating a potential downside of 14.17%. Iovance Biotherapeutics has a consensus price target of $8.89, indicating a potential upside of 5.44%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Exelixis has a net margin of 35.33% compared to Iovance Biotherapeutics' net margin of -89.11%. Exelixis' return on equity of 42.17% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Exelixis has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34
Iovance Biotherapeutics	$263.50M	14.49	-$390.98M	-$0.73	N/A

Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

In the previous week, Exelixis had 15 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 21 mentions for Exelixis and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Exelixis' score of 1.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Exelixis beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

Iovance Biotherapeutics (NASDAQ:IOVA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Iovance Biotherapeutics presently has a consensus target price of $8.89, suggesting a potential upside of 5.44%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 38.45%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

Iovance Biotherapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Iovance Biotherapeutics' net margin of -89.11%. BioMarin Pharmaceutical's return on equity of 5.32% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	14.49	-$390.98M	-$0.73	N/A
BioMarin Pharmaceutical	$3.22B	3.87	$348.90M	$0.37	174.08

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 6 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat BioMarin Pharmaceutical's score of 0.65 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Iovance Biotherapeutics on 13 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Madrigal Pharmaceuticals?

Iovance Biotherapeutics (NASDAQ:IOVA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Madrigal Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	14.49	-$390.98M	-$0.73	N/A
Madrigal Pharmaceuticals	$958.40M	13.18	-$288.28M	-$12.89	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Iovance Biotherapeutics currently has a consensus target price of $8.89, indicating a potential upside of 5.44%. Madrigal Pharmaceuticals has a consensus target price of $699.64, indicating a potential upside of 27.99%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 6 mentions for Iovance Biotherapeutics and 3 mentions for Madrigal Pharmaceuticals. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Madrigal Pharmaceuticals' score of 1.01 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Iovance Biotherapeutics' net margin of -89.11%. Halozyme Therapeutics' return on equity of 260.98% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Halozyme Therapeutics presently has a consensus price target of $91.20, suggesting a potential downside of 15.08%. Iovance Biotherapeutics has a consensus price target of $8.89, suggesting a potential upside of 5.44%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.33	$316.89M	$3.35	32.06
Iovance Biotherapeutics	$263.50M	14.49	-$390.98M	-$0.73	N/A

In the previous week, Halozyme Therapeutics had 14 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 20 mentions for Halozyme Therapeutics and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Halozyme Therapeutics' score of 0.74 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Iovance Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Arrowhead Pharmaceuticals presently has a consensus target price of $99.15, suggesting a potential upside of 20.00%. Iovance Biotherapeutics has a consensus target price of $8.89, suggesting a potential upside of 5.44%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.48 beat Arrowhead Pharmaceuticals' score of 0.76 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.03	-$1.63M	-$2.25	N/A
Iovance Biotherapeutics	$263.50M	14.49	-$390.98M	-$0.73	N/A

Summary

Arrowhead Pharmaceuticals beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.94B	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.62%	2.55%	9.95%
P/E Ratio	-11.55	12.94	271.79	25.29
Price / Sales	14.49	1,459.61	709.75	113.08
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	4.79	15.81	10.63	6.26
Net Income	-$390.98M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-3.10%	-0.13%	-1.19%	-0.56%
1 Month Performance	31.72%	4.54%	1.99%	-1.04%
1 Year Performance	254.20%	46.20%	21.89%	11.31%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	1.5214 of 5 stars	$8.43 -3.1%	$8.89 +5.4%	+255.7%	$3.94B	$263.50M	N/A	500	Positive News
EXEL Exelixis	3.0297 of 5 stars	$54.64 +0.3%	$50.07 -8.4%	+52.4%	$13.54B	$2.32B	17.18	1,077	Positive News Analyst Revision
BMRN BioMarin Pharmaceutical	4.8232 of 5 stars	$65.23 +0.9%	$88.92 +36.3%	+15.7%	$12.63B	$3.22B	176.30	3,221
MDGL Madrigal Pharmaceuticals	3.2171 of 5 stars	$540.03 +1.2%	$699.64 +29.6%	+21.8%	$12.47B	$958.40M	N/A	90	Positive News
HALO Halozyme Therapeutics	3.3643 of 5 stars	$106.49 +1.1%	$91.20 -14.4%	+41.2%	$12.09B	$1.40B	31.79	390

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. EXEL, BMRN, MDGL, HALO, and ARWR

How does Iovance Biotherapeutics compare to Exelixis?

Summary

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

Summary

How does Iovance Biotherapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. EXEL, BMRN, MDGL, HALO, and ARWR

How does Iovance Biotherapeutics compare to Exelixis?

Do analysts recommend EXEL or IOVA?

Is EXEL or IOVA more profitable?

Which has better valuation and earnings, EXEL or IOVA?

Which has more risk & volatility, EXEL or IOVA?

Does the media favor EXEL or IOVA?

Do insiders & institutionals hold more shares of EXEL or IOVA?

Summary

How does Iovance Biotherapeutics compare to BioMarin Pharmaceutical?

Do analysts recommend IOVA or BMRN?

Which has more risk and volatility, IOVA or BMRN?

Is IOVA or BMRN more profitable?

Which has stronger valuation and earnings, IOVA or BMRN?

Do insiders and institutionals hold more shares of IOVA or BMRN?

Does the media prefer IOVA or BMRN?

Summary

How does Iovance Biotherapeutics compare to Madrigal Pharmaceuticals?

Which has stronger earnings and valuation, IOVA or MDGL?

Is IOVA or MDGL more profitable?

Do institutionals and insiders believe in IOVA or MDGL?

Do analysts recommend IOVA or MDGL?

Does the media refer more to IOVA or MDGL?

Which has more risk & volatility, IOVA or MDGL?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Do institutionals & insiders hold more shares of HALO or IOVA?

Is HALO or IOVA more profitable?

Do analysts rate HALO or IOVA?

Which has more risk & volatility, HALO or IOVA?

Which has stronger valuation & earnings, HALO or IOVA?

Does the media refer more to HALO or IOVA?

Summary

How does Iovance Biotherapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate ARWR or IOVA?

Is ARWR or IOVA more profitable?

Which has more volatility & risk, ARWR or IOVA?

Does the media prefer ARWR or IOVA?

Do insiders & institutionals hold more shares of ARWR or IOVA?

Which has stronger valuation & earnings, ARWR or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools